Skip to main content
graph.swiss
MRK

MRK

102.70 CHF+3.86 (+3.91%)
XSWX:MRKMarket Closed
ListedCHFHealthcareDrug Manufacturers - General73,000 employees

Company Profile

Legal NameMRK
CEOMr. Robert M. Davis J.D.
Headquarters126 East Lincoln Avenue
Phone908 740 4000
Employees (FTE)73,000
SectorHealthcare
IndustryDrug Manufacturers - General

Business Description

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Profitability & Growth

Profitability

Profit Margin+13.59%
Operating Margin+38.60%
Return on Equity (TTM)+18.94%
Return on Assets (TTM)+12.58%

Recent Year-End

Revenue53.17B
Revenue / Share26.42
Gross Profit40.80B
EBITDA29.11B
Diluted EPS2.88
Revenue Growth YoY+4.90%

Balance Sheet Snapshot

Total Cash (MRQ)

4.61B

Total Debt (MRQ)

39.71B

Current Ratio (MRQ)

1.30

Book Value / Share

15.03

Stock Statistics

Shares Outstanding2.47B
Float Shares2.47B
Avg Volume (10d)5
Avg Volume (90d)2
% Held by Insiders+0.06%
% Held by Institutions+82.18%

Valuation

Enterprise Value277.16B
Trailing P/E33.09
Price / Book (MRQ)6.34
EV / Revenue5.21
EV / EBITDA11.61

Price Summary

52-Week Low83.33
52-Week High103.54
50-Day MA94.89
200-Day MA92.73
Beta0.20

Dividends

Forward Div Rate1.37
Forward Div Yield+1.34%
Trailing Div Rate1.37
5Y Avg Div Yield+260.00%
Payout Ratio+23.94%
Ex-Dividend Date2026-06-15